• Haematologica · Sep 2004

    Comparative Study Clinical Trial

    The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.

    • Alessandro Corso, Luciana Barbarano, Patrizia Zappasodi, Roberto Cairoli, Emilio Paolo Alessandrino, Silvia Mangiacavalli, Daris Ferrari, Sergio Fava, Mario Fiumanò, Guido Frigerio, Luciano Isa, Annalisa Luraschi, Catherine Klersy, Alberto De Paoli, Claudio Vergani, Luciano Banfi, Daniele Perego, Gianni Ucci, Graziella Pinotti, Maria Savarè, Lilj Uziel, Alessandro Vismara, Enrica Morra, and Mario Lazzarino.
    • The Division of Hematology from IRCCS Policlinico S. Matteo University of Pavia, Ospedale Niguarda Milano, Italy. a.corso@smatteo.pv.it <a.corso@smatteo.pv.it>
    • Haematologica. 2004 Sep 1; 89 (9): 1124-7.

    Background And ObjectivesStandard treatment for patients with multiple myeloma is debulking chemotherapy with non-alkylating agents followed by a regimen to mobilize peripheral blood stem cells (PBSC) and the transplantation of the mobilized, autologous PBSC. The aim of this study was to evaluate the efficacy of a new regimen and compare it with that of a previous regimen.Design And MethodsIn a large cohort of 106 patients (group I) we administered a new pre-transplant program which includes 2 courses of pulsed-VAD (vincristine, adriamycin, dexamethasone) followed by 2 courses of DCEP (dexamethasone, cyclophosphamide, etoposide and cis-platinum). We compared the efficacy of this new VAD-DCEP sequence, in terms of mobilizing capacity, toxicity and anti-myeloma activity in comparison with that of the previous VAD-high-dose cyclophosphamide program (group II, 40 patients).ResultsIn group I 81/106 (76.4%) patients yielded >or= 4x10(6)/kg CD34+ cells, as did 30/40 (75%) in group II but with a significantly higher toxicity in this latter group. In detail, 9 patients in group I (8.5%) had WHO grade III neutropenia versus 35 in group II (87.5%), 5 patients of group I (4.7%) had grade III thrombocytopenia versus 12 patients in group II (30%), and 8 patients in group I (7.5%) experienced an infections fever versus 9 patients in group II (22.5%). Therefore, nearly all patients in group II had to be admitted to hospital (39/40, 97.5%). There was a higher percentage of responses (CR+VGPR+PR) in group I than in group II: 73% versus 50% (p=0.02).Interpretation And Conclusionsthe VAD-DCEP sequence has an adequate mobilizing capacity, without significant toxicity, and a good anti-myeloma activity, and therefore represents a safe and effective therapeutic approach for multiple myeloma patients at the onset of their disease.

      Pubmed     Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…